Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred to the company.
The patent “New method for treatment of inflammatory diseases.“, previously granted on most major markets, has now also been approved in Canada.
Einar Pontén, CEO of Lipum, says “-indeed satisfying that our IPR becomes even stronger, and we are about to enhance our strategy even more.”